World's Best Scientists 2026 revealed!
Pierfranco Conte

Pierfranco Conte

D-Index & Metrics

Medicine

D-Index
103
Citations
48520
World Ranking
7241
National Ranking
241

Overview

Pierfranco Conte is affiliated with the University of Padua in Italy. Their research primarily focuses on medicine and biochemistry, genetics, and molecular biology, with a significant emphasis on oncology, pulmonary and respiratory medicine, cancer research, genetics, and radiology, nuclear medicine, and imaging.

The main topics addressed in Conte's work include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer Treatment and Pharmacology

Conte has coauthored extensively with colleagues such as Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Giulia Pasello, and Federica Miglietta. Their collaborations have contributed to a diverse and prolific research output.

Frequently publishing in venues relevant to oncology and cancer research, Conte's work appears in:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • ESMO Open
  • Cancers

Notable recent papers by Conte include:

  • "Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations," 2020, New England Journal of Medicine
  • "Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1," 2020, Annals of Oncology
  • "Evolution of HER2-low expression from primary to recurrent breast cancer," 2021, npj Breast Cancer
  • "A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer," 2020, Clinical Cancer Research
  • "Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment," 2022, ESMO Open

Best Publications

  • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

    H. von der Maase;S.W. Hansen;J.T. Roberts;L. Dogliotti

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

    Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    M.E. Robson;N. Tung;P. Conte;S.-A. Im

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

  • Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

    M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale

  • Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

    J M Nabholtz;K Gelmon;M Bontenbal;M Spielmann

  • Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

    Valentina Guarneri;Antonio Frassoldati;Alberto Bottini;Katia Cagossi

  • Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Edith A. Perez;Carlos Barrios;Wolfgang Eiermann;Masakazu Toi

  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    F. André;E.M. Ciruelos;D. Juric;S. Loibl

  • Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

    Eva Thomas;Josep Tabernero;Monica Fornier;Pierfranco Conté

  • Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.

    PierFranco Conte;Valentina Guarneri

  • Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

    M. V. Dieci;M. C. Mathieu;V. Guarneri;P. Conte

  • Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Javier Cortés;Pierre Fumoleau;Giulia Valeria Bianchi;Teresa M. Petrella

Frequent Co-Authors

Massimo Dominici
Massimo Dominici University of Modena and Reggio Emilia
Alfredo Falcone
Alfredo Falcone University of Pisa
Mario Campone
Mario Campone Grenoble Alpes University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Stefano Indraccolo
Stefano Indraccolo Istituto Oncologico Veneto
Paolo Bruzzi
Paolo Bruzzi Ospedale San Martino
Andrea Ardizzoni
Andrea Ardizzoni University of Bologna
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Romano Danesi
Romano Danesi University of Pisa
Dino Amadori
Dino Amadori University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens doors to a variety of related online degrees and alternative healthcare pathways. For those interested in nutrition, an online dietitian degree can help lay the foundation for roles in clinical nutrition, wellness programs, or food science from a flexible, remote format.

For aspiring administrators, choosing which online healthcare degree programs are recognized for their accreditation by cahme? is crucial, as employers in hospital management and health policy value recognized, credible credentials.

Registered nurses looking to upskill have the option of pursuing an rn to bsn without clinicals path, allowing career advancement with maximum scheduling flexibility.

Meanwhile, advanced practitioners may consider the shortest dnp programs to achieve a Doctorate of Nursing Practice in less time.

Each pathway offers unique advantages, whether your aim is direct patient care, management, or specialized wellness roles. Be sure to research accreditation and program length to find your ideal fit in this rapidly evolving field.

Best Scientists Citing Pierfranco Conte

Trending Scientists

Recently Published Articles